2025-02-12 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**0. Key Figures:**

* **Cumulative Return (MRK):** 42.41%
* **Cumulative Return (VOO):** 120.25%
* **Return Difference (MRK vs VOO):** -77.8%
* **Relative Divergence:** 0.1 (indicating MRK's performance is at the 10th percentile relative to its historical performance against VOO)
* **Current Price:** $86.54
* **5-Day MA:** $87.59
* **20-Day MA:** $95.12
* **60-Day MA:** $98.08
* **RSI:** 28.28
* **PPO:** -1.28


**1. Company Overview and Performance Comparison:**

Merck & Co Inc is a leading global healthcare company focused on developing and providing innovative medicines and vaccines.  While MRK's cumulative return of 42.41% is significantly lower than the S&P 500's (VOO) return of 120.25%, the provided data suggests this underperformance is within the range of its historical relative performance.  The relative divergence of 0.1 shows it currently sits near the lower bound of its historical performance spread against VOO.  The alpha and beta analysis indicates periods of both outperformance and underperformance relative to the market.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -2.0% | 11.8% | -0.1 | 110.1 |
| 2016-2018  | 46.0% | 11.8% | 0.5 | 154.1 |
| 2017-2019  | 44.0% | 11.8% | 0.3 | 188.4 |
| 2018-2020  | 32.0% | 9.4% | 0.2 | 174.8 |
| 2019-2021  | 3.0% | 14.3% | 0.2 | 177.9 |
| 2020-2022  | 47.0% | 14.3% | 0.2 | 265.8 |
| 2021-2023  | 55.0% | 14.3% | 0.3 | 268.4 |
| 2022-2024  | 21.0% | 9.5% | 0.3 | 251.7 |
| 2023-2025  | -44.0% | 12.0% | 0.2 | 218.9 |


**2. Recent Price Movement:**

The current price is slightly below the 5-day moving average, indicating recent downward pressure. It is also significantly below both the 20-day and 60-day moving averages, suggesting a possible downtrend. The small positive daily change (0.16$) doesn't significantly alter this interpretation.

**3. Technical Indicators and Expected Return:**

The RSI of 28.28 suggests the stock is currently in oversold territory.  The negative PPO (-1.28) reinforces this bearish sentiment.  The recent positive relative divergence, while short-term bullish, is countered by the overall bearish trend indicated by the moving averages and other indicators. The projected 738.4% expected return over the long term is exceptionally high and should be viewed with skepticism without deeper justification for such an optimistic forecast.  More conservative projections are needed.

**4. Recent Earnings Analysis:**

The earnings data shows some volatility in EPS and revenue. While revenue has generally been increasing, EPS shows fluctuation. Further analysis is required to determine the drivers behind these trends.  The repetition of the November 2024 data point needs clarification.


| 날짜 | EPS | 매출 |
|---|---|---|
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2024-11-06 | 1.87 | 15.96 B$ |


**5. Financial Information:**

Revenue shows a generally upward trend, while profit margins are relatively stable and high.  Equity and ROE exhibit volatility, with a significant negative ROE in Q4 2023. This requires further investigation to understand the underlying reasons.

Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |
| 2023-09-30 | $41.25B | 11.50% |


**6. Overall Analysis:**

Merck shows signs of both strength (high profit margins, generally increasing revenue) and weakness (underperformance relative to the S&P 500, currently oversold conditions, volatility in EPS and ROE). The extremely high projected long-term return requires further justification and is likely unrealistic. The inconsistent data points (duplicate November 2024 earnings data) need correction.  Further investigation into the drivers behind the volatility in EPS and ROE is crucial before forming a conclusive opinion.  A more in-depth analysis of the company's competitive landscape, pipeline, and overall strategy is needed to provide a comprehensive assessment.  The current data suggests caution, but more information is required for a well-informed investment decision.
